Allarity Therapeutics, Inc. (ALLR)
NASDAQ: ALLR · Real-Time Price · USD
1.240
0.00 (0.00%)
Mar 9, 2026, 1:52 PM EDT - Market open
Allarity Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Selling, General & Admin | 10.23 | 11.44 | 10.03 | 9.96 | 12.36 | 4.1 | Upgrade
|
| Research & Development | 7.57 | 6.89 | 7.9 | 7.64 | 14.2 | 4.22 | Upgrade
|
| Other Operating Expenses | -0.8 | -0.8 | -0.8 | -0.71 | - | - | Upgrade
|
| Operating Expenses | 17 | 17.54 | 17.13 | 16.89 | 26.56 | 8.32 | Upgrade
|
| Operating Income | -17 | -17.54 | -17.13 | -16.89 | -26.56 | -8.32 | Upgrade
|
| Interest Expense | -0.2 | -0.65 | -0.5 | -0.22 | -0.59 | -0.32 | Upgrade
|
| Interest & Investment Income | 0.87 | 0.53 | 0.02 | 0.03 | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | 1.03 | -0.21 | 0.13 | -0.91 | -0.1 | 0.06 | Upgrade
|
| Other Non Operating Income (Expenses) | 0 | 2.68 | 5.65 | 17.13 | 0.35 | 1.56 | Upgrade
|
| EBT Excluding Unusual Items | -15.31 | -15.19 | -11.82 | -0.87 | -26.88 | -7.02 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | -0.12 | -0.5 | 0.71 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | 1.78 | 1.01 | - | Upgrade
|
| Asset Writedown | - | -9.7 | - | -17.57 | - | - | Upgrade
|
| Other Unusual Items | - | - | - | -0.8 | -0.14 | -0.11 | Upgrade
|
| Pretax Income | -15.31 | -24.9 | -11.82 | -17.58 | -26.52 | -6.42 | Upgrade
|
| Income Tax Expense | - | -0.38 | 0.08 | -1.52 | 0.13 | 0.2 | Upgrade
|
| Earnings From Continuing Operations | -15.31 | -24.52 | -11.9 | -16.06 | -26.65 | -6.62 | Upgrade
|
| Minority Interest in Earnings | - | - | - | - | - | 0.02 | Upgrade
|
| Net Income | -15.31 | -24.52 | -11.9 | -16.06 | -26.65 | -6.6 | Upgrade
|
| Preferred Dividends & Other Adjustments | - | 0.64 | 8.52 | 4.99 | - | - | Upgrade
|
| Net Income to Common | -15.31 | -25.15 | -20.42 | -21.05 | -26.65 | -6.6 | Upgrade
|
| Shares Outstanding (Basic) | 11 | 2 | - | - | - | - | Upgrade
|
| Shares Outstanding (Diluted) | 11 | 2 | - | - | - | - | Upgrade
|
| EPS (Basic) | -1.33 | -15.65 | - | - | - | - | Upgrade
|
| EPS (Diluted) | -1.33 | -15.65 | - | - | - | - | Upgrade
|
| Free Cash Flow | -15.08 | -17.65 | -12.75 | -16.84 | -14.89 | -7.25 | Upgrade
|
| Free Cash Flow Per Share | -1.31 | -10.98 | - | - | - | - | Upgrade
|
| EBITDA | -16.97 | -17.53 | -17.09 | -16.83 | -26.45 | -8.27 | Upgrade
|
| D&A For EBITDA | 0.04 | 0.01 | 0.04 | 0.06 | 0.11 | 0.05 | Upgrade
|
| EBIT | -17 | -17.54 | -17.13 | -16.89 | -26.56 | -8.32 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.